Allakos Inc. (NASDAQ:ALLK) is expected to report third quarter earnings results, before market open, on Monday 9th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.82 per share.
Looking ahead, the full year loss are expected at $ 3.1 per share.
Stock Performance
On Friday, shares of Allakos Inc. has traded high as $ 101.04 and has cracked $ 95.88 on the downward trend, reaching $ 99.27 with volume of 154.40 thousand shares.
According to the previous trading day, closing price of $ 99.27, representing a 137.61 % increase from the 52 week low of $ 41.61 and a 29.37 % decrease over the 52 week high of $ 139.99.
The company has a market capital of $ 4.86 billion and is part of the Healthcare sector and Biotechnology industry.
Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc.
